

# Matthew J Lim

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4375927/matthew-j-lim-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62

papers

846

citations

14

h-index

28

g-index

64

ext. papers

1,035

ext. citations

6.6

avg, IF

4.34

L-index

#	Paper	IF	Citations
62	l-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: Hype or hope?. <i>Blood Reviews</i> , <b>2022</b> , 100925	11.1	0
61	Genes modulating intestinal permeability and microbial community are dysregulated in sickle cell disease.. <i>Annals of Hematology</i> , <b>2022</b> , 101, 1009	3	0
60	Piperacillin/Tazobactam and Meropenem Use Increases the Risks for Acute Graft Rejection Following First Kidney Transplantation. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11, 2726	5.1	
59	L-glutamine for sickle cell disease: more than reducing redox.. <i>Annals of Hematology</i> , <b>2022</b> , 1	3	0
58	Hematopoietic Stem Cell Transplant for Sickle Cell Disease: PATIENT SELECTION and Timing Based on Sickle Cell-Related Multiple Chronic Conditions. <i>Cell Transplantation</i> , <b>2021</b> , 30, 9636897211046559	4	1
57	Intestinal pathophysiological abnormalities in steady state and after vaso-occlusive crisis in murine sickle cell disease. <i>British Journal of Haematology</i> , <b>2021</b> ,	4.5	2
56	Sperm protein 17 targeting for epithelial ovarian cancer treatment in the era of modern immunoengineering. <i>Molecular Therapy - Oncolytics</i> , <b>2021</b> , 23, 378-386	6.4	
55	Obesity and diabetes mellitus in patients with sickle cell disease. <i>Annals of Hematology</i> , <b>2021</b> , 100, 2203-2205	1	
54	Allogeneic hematopoietic stem cell transplant for sickle cell disease: The why, who, and what. <i>Blood Reviews</i> , <b>2021</b> , 50, 100868	11.1	1
53	Antibiotics to modify sickle cell disease vaso-occlusive crisis?. <i>Blood Reviews</i> , <b>2021</b> , 50, 100867	11.1	1
52	High incidence of healthcare facility-acquired <i>Clostridium difficile</i> infections in chronic opioid users. <i>Journal of Internal Medicine</i> , <b>2021</b> , 289, 129-130	10.8	2
51	A contemporary review of <i>Clostridioides difficile</i> infections in patients with hematologic diseases. <i>Journal of Internal Medicine</i> , <b>2021</b> , 289, 293-308	10.8	3
50	Antimicrobial therapy during cancer treatment: Beyond antibacterial effects. <i>Journal of Internal Medicine</i> , <b>2021</b> , 290, 40-56	10.8	5
49	Antibiotic use in adults during sickle cell vaso-occlusive crisis: Is it time for a controlled trial?. <i>British Journal of Haematology</i> , <b>2021</b> , 193, 1281-1283	4.5	2
48	Vaso-occlusive crisis in sickle cell disease: a vicious cycle of secondary events. <i>Journal of Translational Medicine</i> , <b>2021</b> , 19, 397	8.5	5
47	Chronic opioid use in patients with sickle cell disease. <i>Hematology</i> , <b>2021</b> , 26, 415-416	2.2	0
46	Clinicopathologic consequences following discontinuation of rifaximin in patients with sickle cell disease. <i>American Journal of Hematology</i> , <b>2020</b> , 95, E151-E153	7.1	2

45	Intestinal pathophysiological and microbial changes in sickle cell disease: Potential targets for therapeutic intervention. <i>British Journal of Haematology</i> , <b>2020</b> , 188, 488-493	4.5	9
44	Rifaximin on intestinally-related pathologic changes in sickle cell disease. <i>American Journal of Hematology</i> , <b>2020</b> , 95, E83-E86	7.1	8
43	Cardiovascular Sequelae of Sickle Cell Disease. <i>Cardiology in Review</i> , <b>2020</b> , 28, 10-13	3.2	1
42	Bidirectional interaction between intestinal microbiome and cancer: opportunities for therapeutic interventions. <i>Biomarker Research</i> , <b>2020</b> , 8, 31	8	13
41	Pharmacoeugenetics of Acute Myeloid Leukemia <b>2019</b> , 541-549		
40	Intestinal injury and gut permeability in sickle cell disease. <i>Journal of Translational Medicine</i> , <b>2019</b> , 17, 183	8.5	22
39	Effects of rifaximin on circulating aged neutrophils in sickle cell disease. <i>American Journal of Hematology</i> , <b>2019</b> , 94, E175-E176	7.1	9
38	Elevated urinary 3-indoxyl sulfate in sickle cell disease. <i>American Journal of Hematology</i> , <b>2019</b> , 94, E162-E164		5
37	Rifaximin for sickle cell disease. <i>American Journal of Hematology</i> , <b>2019</b> , 94, E325-E328	7.1	13
36	Effects of Rifaximin on Intestinal Pathophysiologic Changes Associated with Sickle Cell Disease (SCD). <i>Blood</i> , <b>2019</b> , 134, 2282-2282	2.2	
35	Low Incidence of Hospital-Onset Infection in Sickle Cell Disease. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 887-888	59.2	9
34	Procalcitonin as a biomarker to differentiate bacterial infections from engraftment syndrome following autologous hematopoietic stem cell transplantation for multiple myeloma. <i>American Journal of Hematology</i> , <b>2019</b> , 94, E74-E76	7.1	3
33	Endogenous volatile organic compounds in acute myeloid leukemia: origins and potential clinical applications. <i>Journal of Breath Research</i> , <b>2018</b> , 12, 034002	3.1	5
32	Intestinal microbiome analysis revealed dysbiosis in sickle cell disease. <i>American Journal of Hematology</i> , <b>2018</b> , 93, E91-E93	7.1	25
31	Applicability of and potential barriers preventing allogeneic stem cell transplant in sickle cell patients treated outside a sickle cell program. <i>American Journal of Hematology</i> , <b>2018</b> , 93, E150-E152	7.1	5
30	Intensive induction chemotherapy vs hypomethylating agent-based regimen in patients aged 70 years with newly diagnosed acute myeloid leukemia. <i>Hematological Oncology</i> , <b>2018</b> , 36, 495-497	1.3	
29	Changes in intestinal microbiota and their effects on allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 122-128	7.1	21
28	Late-onset fever and engraftment syndrome following autologous stem cell transplant: Impact on resource utilization. <i>American Journal of Hematology</i> , <b>2018</b> , 93, E336-E338	7.1	2

27	Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors. <i>OncImmunity</i> , <b>2018</b> , 7, e1507670	7.2	72
26	Sleep-disordered breathing in patients with sickle cell disease. <i>Annals of Hematology</i> , <b>2018</b> , 97, 755-762	3	12
25	Monocytes and neutrophils as a predictive marker of response to immune checkpoint inhibitors (ICI) in metastatic non-small cell lung cancer (mNSCLC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e21165-e21165	2.2	1
24	Peripheral monocytes and neutrophils predict response to immune checkpoint inhibitors in patients with metastatic non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , <b>2018</b> , 67, 1365-1370	7.4	12
23	Day 14 bone marrow examination in the management of acute myeloid leukemia. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 1079-1084	7.1	11
22	Vancomycin-resistant enterococci in acute myeloid leukemia and myelodysplastic syndrome patients undergoing induction chemotherapy with idarubicin and cytarabine. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 2565-2572	1.9	6
21	Molecular targeting in acute myeloid leukemia. <i>Journal of Translational Medicine</i> , <b>2017</b> , 15, 183	8.5	24
20	ICU intervention during induction chemotherapy for adult patients with newly diagnosed acute myeloid leukemia. <i>Leukemia Research</i> , <b>2016</b> , 48, 16-9	2.7	0
19	Sickle cell vaso-occlusive crisis: it's a gut feeling. <i>Journal of Translational Medicine</i> , <b>2016</b> , 14, 334	8.5	6
18	Intestinal dysbiosis and allogeneic hematopoietic progenitor cell transplantation. <i>Journal of Translational Medicine</i> , <b>2016</b> , 14, 335	8.5	4
17	Outcome of acute myeloid leukemia patients with pulmonary nodules of uncertain etiology receiving allogeneic hematopoietic progenitor cell transplant. <i>European Journal of Haematology</i> , <b>2016</b> , 96, 55-9	3.8	1
16	Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia. <i>Blood</i> , <b>2016</b> , 128, 1649-1649	2.2	1
15	Peri-transplant clostridium difficile infections in patients undergoing allogeneic hematopoietic progenitor cell transplant. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 291-4	7.1	9
14	IV pentamidine for primary PJP prophylaxis in adults undergoing allogeneic hematopoietic progenitor cell transplant. <i>Bone Marrow Transplantation</i> , <b>2015</b> , 50, 1253-5	4.4	10
13	Inferior outcome after allogeneic transplant in first remission in high-risk AML patients who required more than two cycles of induction therapy. <i>American Journal of Hematology</i> , <b>2015</b> , 90, 715-8	7.1	3
12	Phase 2 Study of Epigenetic Priming Using Decitabine Followed By Cytarabine As an Induction Regimen in Older Patients with Newly Diagnosed Acute Myeloid Leukemia. <i>Blood</i> , <b>2015</b> , 126, 3739-3739	2.2	1
11	A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies. <i>Cancer Immunity</i> , <b>2010</b> , 10, 8		33
10	Cancer immunotherapy targeting Sp17: when should the laboratory findings be translated to the clinics?. <i>American Journal of Hematology</i> , <b>2005</b> , 80, 6-11	7.1	28

9	Sp17 gene expression in myeloma cells is regulated by promoter methylation. <i>British Journal of Cancer</i> , <b>2004</b> , 91, 1597-603	8.7	20
8	Combined real time PCR and immunohistochemical evaluation of sperm protein 17 as a cancer-testis antigen. <i>European Journal of Haematology</i> , <b>2004</b> , 73, 280-4	3.8	12
7	Expression of sperm protein 17 (Sp17) in ovarian cancer. <i>International Journal of Cancer</i> , <b>2004</b> , 108, 805-115	7.5	64
6	Identification of a sperm protein 17 CTL epitope restricted by HLA-A1. <i>International Journal of Cancer</i> , <b>2003</b> , 107, 863-5	7.5	15
5	Tumor vaccine for ovarian carcinoma targeting sperm protein 17. <i>Cancer</i> , <b>2002</b> , 94, 2447-53	6.4	57
4	Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma. <i>Blood</i> , <b>2002</b> , 100, 961-5	2.2	82
3	Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma. <i>Blood</i> , <b>2001</b> , 97, 1508-10	2.2	119
2	Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector. <i>Cancer Gene Therapy</i> , <b>2001</b> , 8, 948-57	5.4	58
1	Expression of surface CD40 and immunocytochemical actin-bundling protein fascin in dendritic cells from multiple myeloma treated with retinoids during their differentiation in vitro. <i>In Vitro Cellular and Developmental Biology - Animal</i> , <b>2001</b> , 37, 641-3	2.6	